MedTrace Logo

Medical Care Versus Ventricular Assist Device for the Management of End-stage Heart Failure (MEVADE)

NCT03105726 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 224

Last updated 2017-04-27

No results posted yet for this study

Summary

End-stage heart failure (ESHF) represents a major burden in terms of quality of life, mortality and costs. The current practice in France is to treat patients with ESHF by a combination of drugs and lifestyle interventions before proposing heart transplant (HT) if there is no contraindication. In the Heart and Diabetes Center of Bad Oyenhausen (BO) in Germany, patients presenting with ESHF are preferentially managed by ventricular assist device (VAD) therapy. The primary purpose of this study was to compare the outcomes of these two strategies in the management of ESHF and associated consumption of resources.

Conditions

Sponsors & Collaborators

  • Joe Elie Salem

    lead OTHER

Principal Investigators

  • Isabelle IDZ Durand-Zaleski, MD, PhD · UMRS 1123, Unité de Recherche Clinique en Économie de la Santé, Ile de France Hôpital Hôtel Dieu, Santé Publique Hôpital Henri Mondor, Paris, France;

  • Nadia NA Aissaoui, MD, PhD · HEGP and Université Paris Descartes

  • Jan JG Gummert, M.D, PhD · Herz und Diabetes Zentrum, NRW

  • Jean-Yves JYF Fagon, MD, PhD

Eligibility

Min Age
18 Years
Max Age
76 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2013-10-31
Completion
2014-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03105726 on ClinicalTrials.gov